Insider Selling: PTC Therapeutics (NASDAQ:PTCT) Insider Sells 3,019 Shares of Stock

PTC Therapeutics, Inc. (NASDAQ:PTCT) insider Eric Pauwels sold 3,019 shares of the business’s stock in a transaction dated Wednesday, February 18th. The shares were sold at an average price of $69.36, for a total value of $209,397.84. Following the completion of the transaction, the insider owned 77,122 shares in the company, valued at $5,349,181.92. This trade represents a 3.77% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website.

Eric Pauwels also recently made the following trade(s):

• On Monday, January 12th, Eric Pauwels sold 1,024 shares of PTC Therapeutics stock. The stock was sold at an average price of $78.70, for a total value of $80,588.80.
• On Friday, January 9th, Eric Pauwels sold 1,722 shares of PTC Therapeutics stock. The shares were sold at an average price of $77.41, for a total value of $133,300.02.
• On Thursday, January 8th, Eric Pauwels sold 4,602 shares of PTC Therapeutics stock. The stock was sold at an average price of $76.50, for a total value of $352,053.00.
• On Wednesday, January 7th, Eric Pauwels sold 1,352 shares of PTC Therapeutics stock. The shares were sold at an average price of $77.48, for a total transaction of $104,752.96.
• On Tuesday, January 6th, Eric Pauwels sold 1,789 shares of PTC Therapeutics stock. The shares were sold at an average price of $76.95, for a total transaction of $137,663.55.
• On Friday, December 19th, Eric Pauwels sold 20,508 shares of PTC Therapeutics stock. The stock was sold at an average price of $77.26, for a total transaction of $1,584,448.08.
• On Wednesday, December 17th, Eric Pauwels sold 40,290 shares of PTC Therapeutics stock. The shares were sold at an average price of $75.43, for a total transaction of $3,039,074.70.
• On Thursday, December 18th, Eric Pauwels sold 3,202 shares of PTC Therapeutics stock. The stock was sold at an average price of $75.06, for a total transaction of $240,342.12.

PTC Therapeutics Stock Performance

NASDAQ:PTCT traded up $0.76 during mid-day trading on Friday, reaching $70.66. The stock had a trading volume of 2,532,077 shares, compared to its average volume of 1,290,685. The firm has a market capitalization of $5.67 billion, a price-to-earnings ratio of 8.25 and a beta of 0.48. PTC Therapeutics, Inc. has a twelve month low of $35.95 and a twelve month high of $87.50. The business has a 50 day simple moving average of $75.01 and a 200 day simple moving average of $67.78.

PTC Therapeutics (NASDAQ:PTCT) last released its earnings results on Thursday, February 19th. The biopharmaceutical company reported ($1.67) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.21) by ($1.46). The business had revenue of $164.68 million for the quarter, compared to analyst estimates of $281.45 million. PTC Therapeutics had a negative return on equity of 194.11% and a net margin of 42.25%.The business’s revenue for the quarter was down 22.7% on a year-over-year basis. During the same quarter in the previous year, the firm posted ($0.85) EPS. As a group, sell-side analysts expect that PTC Therapeutics, Inc. will post -4.52 earnings per share for the current year.

Hedge Funds Weigh In On PTC Therapeutics

Hedge funds have recently bought and sold shares of the stock. Mcguire Capital Advisors Inc. purchased a new stake in shares of PTC Therapeutics in the fourth quarter valued at $397,000. Invesco Ltd. increased its position in PTC Therapeutics by 38.7% during the 4th quarter. Invesco Ltd. now owns 434,285 shares of the biopharmaceutical company’s stock worth $32,988,000 after purchasing an additional 121,228 shares in the last quarter. Summit Global Investments acquired a new position in PTC Therapeutics in the 4th quarter valued at about $242,000. State of Tennessee Department of Treasury purchased a new position in PTC Therapeutics in the 4th quarter valued at about $2,465,000. Finally, Mackenzie Financial Corp lifted its holdings in PTC Therapeutics by 17.4% in the 4th quarter. Mackenzie Financial Corp now owns 236,909 shares of the biopharmaceutical company’s stock valued at $18,015,000 after purchasing an additional 35,117 shares in the last quarter.

Analysts Set New Price Targets

Several equities research analysts have commented on the stock. Jefferies Financial Group boosted their target price on shares of PTC Therapeutics from $63.00 to $77.00 and gave the stock a “buy” rating in a research report on Tuesday, October 28th. Royal Bank Of Canada lowered their target price on shares of PTC Therapeutics from $87.00 to $82.00 and set a “sector perform” rating on the stock in a research report on Friday. Wall Street Zen raised shares of PTC Therapeutics from a “hold” rating to a “buy” rating in a report on Saturday, January 3rd. Wells Fargo & Company decreased their price target on PTC Therapeutics from $93.00 to $86.00 and set an “overweight” rating on the stock in a research note on Friday. Finally, The Goldman Sachs Group upped their price target on PTC Therapeutics from $44.00 to $50.00 and gave the stock a “sell” rating in a report on Wednesday, November 5th. Ten investment analysts have rated the stock with a Buy rating, five have issued a Hold rating and one has given a Sell rating to the stock. According to data from MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and a consensus target price of $80.73.

Key PTC Therapeutics News

Here are the key news stories impacting PTC Therapeutics this week:

• Positive Sentiment: Company reported full‑year 2025 product and royalty revenue that exceeded guidance, strong early commercial uptake of Sephience™ (Q4 Sephience revenue $92M; 2025 Sephience revenue $111M), and $1.95B cash on hand — supports runway for commercialization and R&D. Read More.
• Positive Sentiment: Bank of America trimmed its price target from $97 to $93 but kept a “buy” rating, signaling continued analyst conviction and providing potential support for the stock. Read More.
• Neutral Sentiment: Full Q4 earnings call transcript and highlights are available for investors parsing management commentary for drivers of the revenue miss (useful to judge one‑time items vs. sustained weakness). Read More.
• Negative Sentiment: Q4 results missed badly: EPS of ($1.67) vs. consensus ($0.21) and revenue $164.7M vs. $281.5M expected — revenue fell ~22.7% YoY. That miss is the primary near‑term driver of investor concern. Read More.
• Negative Sentiment: Management set FY‑2026 revenue guidance of $700M–$800M versus street consensus near $974M — a sizable downward gap that reduces near‑term upside and likely drove negative sentiment. Read More.
• Negative Sentiment: Regulatory uncertainty after PTC withdrew a Translarna NDA has prompted new questions about that program’s prospects and potential revenue contribution. Read More.
• Negative Sentiment: Insider selling: VP Mark Elliott Boulding sold ~5,894 shares across Feb. 17–18 (recent Form 4 filings), a modest but visible reduction that some investors view negatively. Read More.

About PTC Therapeutics

PTC Therapeutics, Inc is a biopharmaceutical company focused on the discovery, development and commercialization of small molecule and biologic therapies for the treatment of rare genetic disorders. Since its founding in 1998, PTC has dedicated its efforts to addressing high unmet medical needs by targeting underlying genetic causes of disease. The company’s research platform emphasizes mechanisms such as nonsense suppression and RNA modulation, enabling the development of novel treatments for conditions with limited therapeutic options.

Among PTC’s approved products is Translarna (ataluren), a first-in-class therapy designed to treat nonsense mutation Duchenne muscular dystrophy in select markets.